New RNA Treatment Could Change How We Fight Type 2 Diabetes

Researchers at Murdoch University are developing a groundbreaking RNA-based treatment that targets insulin resistance directly, addressing what they consider a root cause of type 2 diabetes rather than just managing symptoms. This new approach could offer hope for people who struggle with current treatments that don't fully address the underlying problem of how their bodies process insulin.

How Does This New Treatment Work Differently?

Unlike traditional diabetes medications that focus on managing blood sugar levels after the fact, this RNA-based therapy aims to address the communication breakdown between insulin and cells. When you have type 2 diabetes, your body produces insulin, but your cells become resistant to it—like having a key that no longer fits the lock properly. Professor Rakesh Veedu, the chemical biologist leading this research at Murdoch University's Personalised Medicine Centre, explains that current treatments miss this crucial step.

"Current treatments do not directly treat insulin signalling impairment to manage insulin resistance and high blood sugar," Professor Veedu said. "Our goal is to develop a therapy that's not only more effective in addressing insulin resistance, but also safer and easier to use."

What Makes RNA Medicine Different From Current Options?

The research team, working through the pharmaceutical startup ProGenis that Professor Veedu co-founded, is focusing on what they call "a new class of RNA-based medicines." RNA, or ribonucleic acid, is like your body's messenger system—it carries instructions from your DNA to make proteins. By using RNA therapeutically, researchers aim to address insulin signalling impairment at the cellular level.

This approach represents a significant shift from current diabetes management strategies, which typically include:

• Metformin and similar drugs: These help reduce glucose production in the liver and improve insulin sensitivity, but don't directly target the insulin signaling problem that Professor Veedu's team is addressing
• Insulin injections: These provide external insulin when the body can't produce enough, but don't address why cells aren't responding properly to the insulin that's already there
• Lifestyle modifications: Diet and exercise help manage blood sugar levels but may not be sufficient for addressing the underlying insulin resistance that this RNA therapy targets

When Could This Treatment Become Available?

The research is approaching a critical milestone—human clinical trials. While the team hasn't announced specific timelines, moving from laboratory research to human trials represents a major step forward in the development process. Clinical trials typically take several years to complete, involving multiple phases to test safety and effectiveness before any new treatment could become widely available.

This research offers a glimpse of potentially more targeted treatment options for people living with type 2 diabetes. The focus on insulin resistance as a root cause, rather than just managing elevated glucose levels, could represent a fundamental shift in how we approach this chronic condition that affects everything from wound healing to cardiovascular health. The small team at Murdoch University's Personalised Medicine Centre continues working toward what could reshape diabetes treatment if their RNA-based approach proves successful in human trials.